Search company, investor...
Sage Science company logo

Sage Science

sagescience.com

Stage

Loan | Alive

Total Raised

$18.12M

Last Raised

$680K | 3 yrs ago

About Sage Science

Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.

Headquarters Location

500 Cummings Center Suite 3150

Beverly, Massachusetts, 01915,

United States

978-922-1832

Missing: Sage Science's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sage Science's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sage Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sage Science is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health IT

7,901 items

Sage Science Patents

Sage Science has filed 21 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Cell culture
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2016

1/3/2023

Molecular biology, Genetics, DNA, Biotechnology, Genomics

Grant

Application Date

11/21/2016

Grant Date

1/3/2023

Title

Related Topics

Molecular biology, Genetics, DNA, Biotechnology, Genomics

Status

Grant

Latest Sage Science News

Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth

May 13, 2021

Debut webcast to provide deep dive on SAGE-718, the company’s lead neuropsychiatry product candidate being studied for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s, Parkinson’s, and Alzheimer’s diseases Webcast scheduled for 8:30 a.m. ET on Thursday, May 20 May 13, 2021 06:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host the first Sage Science Spotlight webcast focused on an in-depth review of SAGE-718. Sage will provide details on its progress with SAGE-718, the company’s lead neuropsychiatry product candidate being explored for the potential treatment of cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. Sage will also share additional details on the recently announced data from the PARADIGM Study of SAGE-718 in patients with mild cognitive impairment due to Parkinson’s disease and the planned initiation of a Phase 2 placebo-controlled study in Huntington’s disease. Additionally, the Company will discuss the unmet need in Huntington’s disease, with participation and perspectives from a leading neurologist and a patient advocate. The Sage Science Spotlight is a new webcast series designed to take a deeper look at Sage’s work in brain health. It will complement Sage’s annual FutureCast event, which provides an update on the company’s overall research and development strategy and clinical progress in its key depression, neurology and neuropsychiatry franchise programs. Speakers on the May 20th webcast will include: Jim Doherty, Chief Research Officer, Sage Therapeutics Mike Quirk, Vice President, Pharmacology, Sage Therapeutics Aaron Koenig, Executive Medical Director, Early Development, Sage Therapeutics Dr. Samuel Frank, Associate Professor of Neurology, Beth Israel Deaconess Medical Center Seth Rotberg, Patient Advocate (Huntington’s Disease) The webcast can be accessed on the investor page of Sage's website at investor.sagerx.com . A replay of the webcast will be available approximately two hours after the completion of the event. About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com . Forward-Looking Statements Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation: statements regarding our planned research and development activities and the opportunity to help patients in various indications. These statements constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: we may encounter hurdles and delays in initiation, conduct or completion of our planned clinical trials, including as a result of slower than expected site initiation or enrollment; decisions or actions of the FDA may affect the initiation and timing of clinical trials and our ability to proceed with further development; ongoing and future non-clinical and clinical results may not meet their primary or key secondary endpoints or support further development; we may encounter adverse events at any stage of development that negatively impact further development or that require additional nonclinical and clinical work which may not yield positive results; and we may encounter technical and other unexpected hurdles in the development and manufacture of our product candidates which may delay our timing or change our plans, or otherwise negatively impact our business; as well as those risks more fully discussed in the section entitled "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Sage Science Frequently Asked Questions (FAQ)

  • Where is Sage Science's headquarters?

    Sage Science's headquarters is located at 500 Cummings Center, Beverly.

  • What is Sage Science's latest funding round?

    Sage Science's latest funding round is Loan.

  • How much did Sage Science raise?

    Sage Science raised a total of $18.12M.

  • Who are the investors of Sage Science?

    Investors of Sage Science include Paycheck Protection Program, National Human Genome Research Institute, Table Mountain Ventures, Village Ventures and BPEA Private Equity.

  • Who are Sage Science's competitors?

    Competitors of Sage Science include Caliper Life Sciences.

Compare Sage Science to Competitors

ReaMetrix Logo
ReaMetrix

ReaMetrix, Inc. is a US and India-based biotechnology company aiming to provide high quality research and diagnostic assay solutions resulting in a transformation of the cost opportunities available in India into value for both the biotechnology and global health sectors. ReaMetrix's belief is that Indian resources will bring significant value to identifying and addressing the health care needs of the developing world, and that the resulting products will often translate into more affordable alternatives in the developed world.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

Kiyatec Logo
Kiyatec

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

N
Novacta Biosystems

Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

N
Nanosep

Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.